Otsuka's History Profile Sales People Major Milestones Social Responsibility Compliance Corporate Video & Brochure	Font Size: Otsuka America Pharmaceutical, Inc. (OAPI) is a successful, innovative, fast-growing healthcare company that commercializes Otsuka-discovered and other product opportunities in North America, with a strong focus on and commitment to neuroscience, cardiovascular and gastrointestinal therapeutic treatments. Employees 430+ Headquarters Rockville, Maryland 20850 Products ABILIFY®  (aripiprazole) Tablets 1,November 2002 PLETAL ®  (cilostazol) Tablets 2, January 1999 ZEGERID®  (omeprazole/sodium bicarbonate) 3, a Santarus, Inc. product, June 2004 Annual Sales 2004 In excess of US $950 million Annual Sales 2005 In excess of US $1.2 billion Annual Sales 2006 In excess of US $1.6 billion OAPI Vision Statement Otsuka America Pharmaceutical, Inc. will be a successful specialty healthcare company focused in key therapeutic areas principally in the U.S. market, commercializing products innovated by the Otsuka Group and other partners. We will attain the highest ethical and performance standards and provide the highest quality products to benefit patients and the healthcare community. OAPI Core Values Individual Respect: All individuals are valuable and treated with dignity. Integrity: Be true to yourself and others. Commitment: Personal dedication to the success of the Company. Excellence: Achieving the highest professional standards and performance. Collaboration: Working together to create synergy. Customer Focus: Align the Company to meet customer needs. 1 Please see FULL PRODUCT INFORMATION including Boxed WARNINGS for ABILIFY. 2 Please see FULL PRODUCT INFORMATION including Boxed WARNINGS for PLETAL. 3 Please see FULL PRODUCT INFORMATION for ZEGERID.
* OAPI, OPDC, and OMML are subsidiaries of Otsuka America, Inc. (OAI), a holding company established by OPC in the U.S. in 1989